Due to health issues, this site is no longer maintained and will be shut down shortly. |
Salarius Pharmaceuticals, Inc. a clinical-stage oncology company, develops therapies for the treatment of patients with various cancers. The company's lead candidate is Seclidemstat, which is in clinical development for the treatment of Ewing sarcoma, as well as advanced solid tumors, including prostate, breast, and ovarian cancers. Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.
$2.11 +0.06 (2.93%)
As of 03/24/2023 16:30:00 EST IEX book CBOE book
2022 © Stock Market MBA, Inc.